Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress

[PR Newswire] – NORTH CHICAGO, Ill., Oct. 5, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that 26 abstracts on HUMIRA ® (adalimumab) and hidradenitis suppurativa (HS), … Read . . . → Read More: Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress Similar Articles: Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015 Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie’s Acquisition of Pharmacyclics Company Update (NYSE:ABBV): AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015